# methods-audit — claim 02ef728775f1cee60872237b9681256b1859603d89a49e6d7cb8dd5a611372bb

Claim: Reported finding from PMID 42340618 (Quality of life with palbociclib plus tamoxifen in hormone receptor-positive, HER2-negative advanced breast cancer: results from PATHWAY, an Asian international, double-blind, randomized phase 3 trial): The combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression.
Source: PMID 42340618 (https://pubmed.ncbi.nlm.nih.gov/42340618/)
Checked: 2026-09-25T08:11:42.644Z

## Method
1. Fetched abstract via NCBI efetch.
2. Checklist audit (qwen3:8b, temp 0): design in source: not stated; design matches claim: false; endpoint matches: n/a; population matches: n/a; contradiction: true.
3. Notes: The claim states that 'the combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression.' However, the source abstract indicates that 'no significant differences were observed in LSM changes in scores from baseline in global QoL' and 'no clinically meaningful differences between treatment arms were found in the LSM changes in scores from baseline.' Additionally, the conclusion of the abstract states that 'the combination of palbociclib and tamoxifen delayed deterioration in patients' QoL while they experienced reduced risk for disease progression,' which is consistent with the claim. However, the results section contradicts the claim by showing no significant differences in QoL scores. Therefore, the claim is not fully supported by the source abstract.
4. Deterministic numeric grounding: missing tokens: none.

## Result
refutes (confidence 7500 bps)

Limitations: abstract-level check only; full text not reviewed.
Source sha256: 229f16ea6c34bf8402ff0cb67a5fb8156b4a400f4f1729a4a57bef9af0140755